BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

February 22, 2024

https://www.globenewswire.com/news-release/2024/02/22/2834007/0/en/BRIGHT-GREEN-CORPORATION-GAINS-MOMENTUM-FOR-THEIR-DRUGS-MADE-IN-AMERICA-PLATFORM-WITH-APPROVAL-FOR-THE-RESEARCH-PRODUCTION-AND-MANUFACTURING-OF-ALL-SCHEDULE-I-AND-SCHEDULE-II-PLANT.html

BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION

GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq:BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, pending: erythroxylon coca (cocaine)

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.